Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to $29.7 million.

  • Maravai Lifesciences Holdings' Capital Expenditures fell 65.94% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year decrease of 58.42%. This contributed to the annual value of $29.7 million for FY2024, which is 54.76% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Capital Expenditures stood at $29.7 million for FY2024, which was down 54.76% from $65.6 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Capital Expenditures ranged from a high of $65.6 million in FY2023 and a low of $14.8 million during FY2021.
  • Its 3-year average for Capital Expenditures is $37.4 million, with a median of $29.7 million in 2024.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 283.58% in 2023, then crashed by 54.76% in 2024.
  • Yearly analysis of 5 years shows Maravai Lifesciences Holdings' Capital Expenditures stood at $25.4 million in 2020, then slumped by 41.55% to $14.8 million in 2021, then increased by 15.08% to $17.1 million in 2022, then skyrocketed by 283.58% to $65.6 million in 2023, then plummeted by 54.76% to $29.7 million in 2024.